UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005692
Receipt number R000006734
Scientific Title I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)
Date of disclosure of the study information 2011/06/01
Last modified on 2011/12/02 02:09:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)

Acronym

I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone

Scientific Title

I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)

Scientific Title:Acronym

I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone

Region

Japan


Condition

Condition

Thyroid cancer

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the clinical efficacy of I-131 therapy with recombinant human thyroid-stimulating hormone in thyroid cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Assessment of anti-tumor effects with tumor size and tumor markers

Key secondary outcomes

Assessment of harmful effects in bone marrow, digestive organ, and salivary gland


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

recombinant human thyroid-stimulating hormone

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) a patient who underwent total thyroidectomy for thyroid cancer
2) a patient with distant metastases of thyroid cancer
3) a patient whose endogenous thyroid-stimulating hormone can not be secreted because of pituitary surgery

Key exclusion criteria

1) pregnant female and feeding female
2) a patient with disturbed consciousness
3) expected life interval less than 1 month
4) risks for the central nerve system during treatment
5) when medical staff determine that treatment can not be properly carried out

Target sample size

1


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Daiki Kayano

Organization

Kanazawa University Hospital

Division name

Department of Nuclear Medicine

Zip code


Address

13-1 Takara-machi, Kanazawa, Ishikawa

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Daiki Kayano

Organization

Kanazawa University Hospital

Division name

Department of Nuclear Medicine

Zip code


Address

13-1 Takara-machi, Kanazawa, Ishikawa

TEL


Homepage URL


Email



Sponsor or person

Institute

Kanazawa University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2011 Year 01 Month 13 Day

Date of IRB


Anticipated trial start date

2011 Year 01 Month 01 Day

Last follow-up date

2014 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 06 Month 01 Day

Last modified on

2011 Year 12 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006734